Revmatologicky Ustav
- Address
- lock Available on a paid plan
Revmatologicky Ustav - Rheumatology Research Institute
Revmatologicky Ustav is a leading rheumatology research center specializing in comprehensive clinical trials across a broad spectrum of autoimmune and inflammatory rheumatic diseases. The institute demonstrates exceptional expertise in evaluating novel biologic therapies, targeted synthetic disease-modifying antirheumatic drugs (DMARDs), and innovative treatment approaches for complex systemic autoimmune conditions.
- Psoriatic arthritis research, including studies of biologics (guselkumab, tildrakizumab, bimekizumab) and JAK inhibitors (deucravacitinib, zasocitinib) in both biologic-naïve and anti-TNF experienced populations
- Systemic lupus erythematosus and lupus nephritis investigations, featuring advanced therapies including CAR-T cell therapy (rapcabtagene autoleucel) and novel biologics (ianalumab, cenerimod, obinutuzumab)
- Rheumatoid arthritis clinical trials evaluating biosimilars, comparative effectiveness studies (abatacept vs adalimumab), and novel immunomodulatory agents
- Specialized research in spondyloarthropathies, inflammatory myopathies, systemic sclerosis, polymyalgia rheumatica, giant cell arteritis, and osteoarthritis
The center's research portfolio encompasses both early-phase development studies and Phase III pivotal trials, with particular emphasis on personalized medicine approaches and glucocorticoid-sparing regimens. The institute demonstrates strong capabilities in conducting complex withdrawal-retreatment studies, long-term safety extension trials, and innovative cell-based therapies for refractory autoimmune conditions, positioning itself at the forefront of rheumatologic research advancement.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 76 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1Novartis Pharma AG6active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG14trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Revmatologicky Ustav
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Mycophenolate Mofetil | 6 | Unknown | 2022-07-14 | 2025-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.